Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials - PubMed (original) (raw)
Review
Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials
Yifei Zhang et al. Diabetes Metab Res Rev. 2014 Mar.
Abstract
Background: Dipeptidyl peptidase-IV (DPP-4) inhibitors and sulfonylureas are two important second-line anti-diabetic agents. The objective of this research was to evaluate the efficacy and safety of DPP-4 inhibitors compared with sulfonylureas by meta-analytic approach of available randomized studies.
Methods: We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials databases up to 30 June 2013, collecting all randomized clinical trials with a treatment duration of ≥18weeks. Data on glycated haemoglobin (HbA1c ), body weight, hypoglycaemia, total adverse events, and cardiovascular events were retrieved and analysed.
Results: The analysis included 12 randomized studies comprising 10 982 patients with type 2 diabetes mellitus. On the basis of meta-analysis, sulfonylureas lowered HbA1c significantly more than DPP-4 inhibitors with weighted mean difference (WMD) of 0.105 [95% confidence interval (CI) 0.103 to 0.107]. The results were consistent in trials with longer (>32 weeks) or shorter (≤32 weeks) duration; however, DPP-4 inhibitors showed greater reduction in HbA1c compared with the second-generation sulfonylureas and in patients with baseline eGFR < 50 mL/min/1.73 m(2) . Patients treated with DPP-4 inhibitors are less likely to achieve HbA1c < 7% compared with sulfonylureas [Mantel-Haenszel odds ratio (MH-OR) 0.91; 95% CI 0.84 to 0.99]. DPP-4 xinhibitors were associated with a reduction in body weight (WMD -1.652; 95% CI -1.658 to -1.646) and lower risk of hypoglycaemia (MH-OR, 0.13; 95% CI 0.11 to 0.16), total adverse events (MH-OR, 0.79; 95% CI 0.72 to 0.87), and cardiovascular events (MH-OR, 0.53; 95% CI 0.32 to 0.87) compared with sulfonylureas.
Conclusion: Although DPP-4 inhibitors are less efficacious compared with sulfonylureas, they demonstrate a beneficial effect on body weight, episodes of hypoglycaemia, and total adverse events.
Keywords: body weight; dipeptidyl peptidase-IV; efficacy; hypoglycaemia; safety; sulfonylureas; type 2 diabetes.
Copyright © 2013 John Wiley & Sons, Ltd.
Similar articles
- Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Karagiannis T, et al. BMJ. 2012 Mar 12;344:e1369. doi: 10.1136/bmj.e1369. BMJ. 2012. PMID: 22411919 - The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial.
Zhou JB, Bai L, Wang Y, Yang JK. Zhou JB, et al. Int J Clin Pract. 2016 Feb;70(2):132-41. doi: 10.1111/ijcp.12761. Epub 2015 Dec 28. Int J Clin Pract. 2016. PMID: 26709610 Review. - The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with metformin in 18,980 patients with type-2 diabetes mellitus--a meta-analysis.
Liu X, Xiao Q, Zhang L, Yang Q, Liu X, Xu L, Cheng W. Liu X, et al. Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):687-98. doi: 10.1002/pds.3586. Epub 2014 Mar 18. Pharmacoepidemiol Drug Saf. 2014. PMID: 24639059 Review.
Cited by
- Current Position of Gliclazide and Sulfonylureas in the Contemporary Treatment Paradigm for Type 2 Diabetes: A Scoping Review.
Sahin I, Bakiner O, Demir T, Sari R, Atmaca A. Sahin I, et al. Diabetes Ther. 2024 Aug;15(8):1687-1716. doi: 10.1007/s13300-024-01612-8. Epub 2024 Jun 27. Diabetes Ther. 2024. PMID: 38935188 Free PMC article. Review. - Dipeptidyl peptidase-4 inhibitors versus sulfonylureas on the top of metformin in patients with diabetes and acute myocardial infarction.
Her AY, Choi BG, Rha SW, Kim YH, Jeong MH; Korea Acute Myocardial Infarction Registry (KAMIR)-National Institutes of Health (NIH) investigators. Her AY, et al. Cardiovasc Diagn Ther. 2024 Feb 15;14(1):38-50. doi: 10.21037/cdt-23-349. Epub 2024 Feb 1. Cardiovasc Diagn Ther. 2024. PMID: 38434553 Free PMC article. - Correction to: "Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis".
Jeon WK, Kang J, Kim HS, Park KW. Jeon WK, et al. J Lipid Atheroscler. 2022 Jan;11(1):89-101. doi: 10.12997/jla.2022.11.1.89. Epub 2022 Jan 14. J Lipid Atheroscler. 2022. PMID: 35118026 Free PMC article. - Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin.
Chouchane K, Di Zenzo G, Pitocco D, Calabrese L, De Simone C. Chouchane K, et al. J Transl Med. 2021 Dec 20;19(1):520. doi: 10.1186/s12967-021-03192-8. J Transl Med. 2021. PMID: 34930319 Free PMC article. Review. - Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis.
Jeon WK, Kang J, Kim HS, Park KW. Jeon WK, et al. J Lipid Atheroscler. 2021 May;10(2):210-222. doi: 10.12997/jla.2021.10.2.210. Epub 2021 Jan 25. J Lipid Atheroscler. 2021. PMID: 34095013 Free PMC article. Retracted.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous